Heart disease shouldn’t be a problem anymore.
At least not as big a one as it is today. After all, the major contributors to heart disease accumulate across multiple decades, and the early signs of deteriorating cardiac function can be measured far before first symptoms.
So why, after over 100 years at pole position, is heart disease still the most common cause of death AND the most common cause of shortened lifespan?
The unfortunate reality is that most of us eventually get stuck in the vicious loop of managing existing heart disease - as opposed to preventing heart disease entirely - because we are only told that our heart is unhealthy when our heart disease is in its final stages.
%201.webp)
This is why our team is so excited to launch the CardioFlux Membership Program
Designed to help you track, analyze, and improve your myocardial fitness. Powered by our very own CardioFlux MCG technology, CardioFlux Membership is the easiest, fastest, and safest way to repeatedly measure and monitor heart health over the course of a lifetime.
Our leadership team
Inspired by his late grandfather to found Genetesis, Peeyush currently serves as CEO. Prior to Genetesis, Peeyush helped found Proscia, a global leader in digital pathology. Peeyush originally studied at The Ohio State University, where he dropped out to begin his entrepreneurial career before returning to graduate.
As Chief Operating Officer, Vineet currently oversees full lifecycle medical device development and leads the engineering team that produces CardioFlux MCG. Before joining Peeyush to found Genetesis, Vineet originally studied Electrical and Biomedical Engineering at Case Western University.
As Chief Product and Strategy Officer, Manny manages the building and maintenance of the many software systems that power the CardioFlux MCG platform. Manny originally studied Computer Science and Engineering at The Ohio State University before taking a leave of absence to help co-found Genetesis.
As Chief Medical Officer, Robert plans and executes the clinical research roadmap while also delivering Consults to CardioFlux Members. Before coming on board, he served as the Chair and Medical Director of Emergency Medicine at Ascension St. John Hospital in Detroit, home to one of the nation’s largest Emergency Departments.
Eric currently oversees all financial operations as Chief Financial Officer at Genetesis. Eric has a wealth of experience in public accounting, and in his most recent stint, he oversaw all accounting and finance functions for the entire physician practice at Oncology Hematology Care (acquired by US Oncology), representing over $250 million in annual revenue.
How CardioFlux Came To Be
1963
Over 60 years ago, Syracuse scientists Gerhard Baule and Richard McFee made history when they recorded the magnetic signature of the heart for the very first time, an event that would later be recognized as the beginning of the field of magnetocardiography (or MCG, for short).
2004
The first modern MCG systems utilized SQUIDs, hyper-sensitive devices that could more reliably measure cardiac signal. But, these machines were far too large and expensive for practical use. Even after formal FDA approval, the field of MCG remained relatively dormant.
2013
After stumbling across MCG research, co-founder Peeyush Shrivastava leaves Ohio State University to launch Genetesis with his father and two of his high school friends. The four of them are determined to solve the design and engineering challenges that were preventing mass-market adoption of MCG technology.
2019
After 6 years of persistent research and development, Genetesis finally receives FDA clearance for its CardioFlux MCG system, utilizing new sensor technologies to produce a machine that is far cheaper and easier to operate than previous MCG systems.
2024
With over 10 years of clinical research validating CardioFlux MCG, Genetesis launches the CardioFlux Membership program to make MCG available directly to the general public. In tandem, the team also launches its first-ever CardioFlux Imaging Institute in Cincinnati, Ohio.
Today, Cincinnati. Tomorrow, the world.
Don't see a location that works for you? Join our waitlist to let us know where you'd like to see us open next and get updates once we do.
Building a world without heart disease.
Our guiding mission with CardioFlux is to give people the power to understand how healthy their hearts really are by taking magnetocardiography - which we believe might be the world's most sensitive instrument for recording cardiac function today - and making it available to everyone, everywhere.
We want to see healthcare make the much-needed transition from treating patients to helping people, and we think magnetocardiography will play a key role in how we do this for people's hearts.
Heartcare begins here.
Begin your very own heartcare journey and sign up for a CardioFlux Membership today.
